All In Biotech

Drug Trial Radar · NCT02043678

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 806 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

806

Actual

Start

Mar 30, 2014

Primary completion

Feb 15, 2018

Study completion Feb 8, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Janssen Research & Development, LLC
First posted
Jan 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.

Conditions

  • Prostatic Neoplasms

Interventions

  • Radium-223 dichloride (Xofigo, BAY88-8223)Drug

    50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles

  • Matching placebo (normal saline)Drug

    Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles

  • AbirateroneDrug

    1000 mg once daily, oral, with best supportive care

  • Prednisone/PrednisoloneDrug

    5 mg twice daily, oral, with best supportive care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptomatic Skeletal Event Free Survival (SSE-FS)Time frame: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months

Locations

163 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Anchorage, Alaska

  • Site not named

    Tucson, Arizona

  • Site not named

    Oceanside, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Myers, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Towson, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Burlington, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Traverse City, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Hackensack, New Jersey

  • Site not named

    Poughkeepsie, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Bala-Cynwyd, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Norfolk, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Spokane, Washington

  • Site not named

    Wheeling, West Virginia

  • Site not named

    East Melbourne, Australia

  • Site not named

    Randwick, Australia

  • Site not named

    St Leonards, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    East Bentleigh, Victoria, Australia

  • Site not named

    Fitzroy, Victoria, Australia

  • Site not named

    Heidelberg, Victoria, Australia

  • Site not named

    Brussels, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Edegem, Belgium

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.